Ionis to Host 2024 Virtual Annual Meeting of Stockholders
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2024 virtual Annual Meeting of Stockholders followed by a ...
Ionis Pharmaceuticals: A Strong Buy on Diverse Pipeline and Positive Clinical Milestones
Here's What Analysts Are Forecasting For Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) After Its First-Quarter Results
Last week, you might have seen that Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) released its quarterly result to the market. The early response was not positive, with shares down 6.8% to US$40.16 in the
The Analyst Landscape: 8 Takes On Ionis Pharmaceuticals
Ratings for Ionis Pharmaceuticals (NASDAQ:IONS) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.The table below summarizes their recent ratin
Wells Fargo Adjusts Ionis Pharmaceuticals Price Target to $82 From $85, Maintains Overweight Rating
Ionis Pharmaceuticals (IONS) has an average rating of outperform and price targets ranging from $33 to $85, according to analysts polled by Capital IQ. Price: 40.43, Change: -0.51, Percent Change: -1.
Ionis Pharmaceuticals Price Target Cut to $82.00/Share From $85.00 by Wells Fargo
Ionis Pharmaceuticals Price Target Cut to $82.00/Share From $85.00 by Wells Fargo
Ionis Pharmaceuticals Is Maintained at Overweight by Wells Fargo
Ionis Pharmaceuticals Is Maintained at Overweight by Wells Fargo
Wells Fargo Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $82
Wells Fargo analyst Yanan Zhu maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $85 to $82.
Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss
Ionis Pharmaceuticals: Advancing Pipeline and Path to Profitability Justify Buy Rating
RBC Capital Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)
Ionis Pharmaceuticals: A Buy Rating With Promising Drug Developments and Market Potential
Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Ionis Pharmaceuticals (IONS) and Premier (PINC)
Ionis Pharmaceuticals Price Target Maintained With a $60.00/Share by Needham
Ionis Pharmaceuticals Price Target Maintained With a $60.00/Share by Needham
Needham Reiterates Buy on Ionis Pharmaceuticals, Maintains $60 Price Target
Needham analyst Joseph Stringer reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $60 price target.
Ionis Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 46.59% Needham → $60 Reiterates Buy → Buy 04/10/2024 — Wolfe Research Upgrades Peer Perform →
Ionis Pharmaceuticals Inc (IONS) Q1 2024 Earnings Call Transcript Highlights: Key Developments ...
Earnings Call Summary | Ionis Pharmaceuticals(IONS.US) Q1 2024 Earnings Conference
The following is a summary of the Ionis Pharmaceuticals, Inc. (IONS) Q1 2024 Earnings Call Transcript:Financial Performance:Ionis Pharmaceuticals reported first-quarter revenues of $119 million, half
Ionis Pharmaceuticals(IONS.US) Director Sells US$256.28K in Common Stock
$Ionis Pharmaceuticals(IONS.US)$ Director KLEIN JOSEPH III sold 6,000 shares of common stock on May 3, 2024 at an average price of $42.7128 for a total value of $256.28K.Source: Announcement What is s
Ionis Pharmaceuticals Insider Sold Shares Worth $256,277, According to a Recent SEC Filing
Joseph Iii Klein, Director, on May 03, 2024, sold 6,000 shares in Ionis Pharmaceuticals (IONS) for $256,277. Following the Form 4 filing with the SEC, Klein has control over a total of 16,446 shares o
No Data